<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>Studies</title>
  <style>
    body {
      font-family: sans-serif;
      line-height: 1.6;
      margin: 0;
      padding: 0;
    }

    header, section {
      padding: 2em;
    }

    header {
      background: #333;
      color: white;
      text-align: center;
    }

    section {
      border-bottom: 1px solid #ccc;
    }

    h2 {
      margin-top: 0;
    }

    /* nav {
      background: #f4f4f4;
      padding: 1em;
      text-align: center;
    }

    nav a {
      margin: 0 1em;
      text-decoration: none;
      color: #333;
    }

    nav a:hover {
      text-decoration: underline;
    } */

    nav {
  background: #f4f4f4;
  padding: 1em;
  text-align: left; /* better for vertical layout */
  max-width: 300px; /* constrain nav width */
  margin: 0 auto; /* center nav block */
}

nav a {
  display: block; /* stack vertically */
  margin: 0.3em 0; /* less margin top and bottom */
  padding: 0.3em 0;
  font-size: 0.9em; /* smaller font size */
  color: #333;
  text-decoration: none;
  border-left: 3px solid transparent;
  transition: border-color 0.3s;
}

nav a:hover {
  border-left: 3px solid #007BFF; /* blue highlight on hover */
  background: #e1eaff; /* subtle background highlight */
  text-decoration: none; /* keep consistent */
}

  </style>
</head>
<body>

  <header>
    <h1>
      Case Studies
    </h1>
    <p>Select a study below</p>
  </header>

  <nav>
    <a href="#section1">Arterial Plaque Outcome Case Study Outline</a>
    <a href="#section2">Asthma Outcome Case Study Outline</a>
    <a href="#section3">Bronchiectasis Outcome Case Study Outline</a>
    <a href="#section4">Crohn's Outcome Case Study Outline</a>
    <a href="#section5">Cystic Fibrosis Outcome Case Study Outline</a>
    <a href="#section6">Parkinson's Outcome Case Study Outline</a>
    <a href="#section7">Ulcerative Colitis Outcome Case Study Outline</a>
    <!-- <a href="#section8">Section 4</a> -->
  </nav>

  <section id="section1">
    <section id="case-study">
      <h2>Arterial Plaque Outcome Case Study Outline</h2>
      <!-- <h2>Outcome Case Study Outline</h2> -->
      <p><strong>Evaluating the Effect of a Dietary Supplement containing Nattokinase and soluble Stacked Terpenes (Borneol and Trans Cinnamaldehyde) (NBT) on Arterial Plaque Reduction in Adults with Mild to Moderate Atherosclerosis.</strong></p>
    
      <h3>1. Introduction</h3>
      <h4>1.1 Title</h4>
      <p>Study and evaluation of the effectiveness of NBT supplementation in reducing arterial plaque levels and improving vascular health in adults with mild to moderate atherosclerosis.</p>
    
      <h4>1.2 Study Objectives</h4>
      <p><strong>Primary Objective:</strong> To evaluate the effect of oral NBT supplementation in adults with moderate arterial plaque.</p>
      <p><strong>Secondary Objectives:</strong></p>
      <ul>
        <li>Evaluate quality of life improvements.</li>
        <li>Assess tolerability of NBT supplementation.</li>
      </ul>
    
      <h4>1.3 Study Design</h4>
      <p><strong>Type:</strong> Case study</p>
      <p><strong>Duration:</strong> 16 weeks</p>
      <p><strong>Setting:</strong> Outpatient clinics and research centers</p>
      <p><strong>Participants:</strong></p>
      <ul>
        <li>20 Adults aged 40-75 years</li>
        <li>Diagnosed with mild to moderate atherosclerosis based on medical history and imaging</li>
        <li>Willing to comply with the study protocol and provide informed consent</li>
        <li>No major cardiovascular events in the last 6 months</li>
      </ul>
      <p><strong>Exclusion Criteria:</strong></p>
      <ul>
        <li>Severe cardiovascular disease</li>
        <li>Active bleeding disorders or history of major bleeding</li>
        <li>Pregnancy or breastfeeding</li>
        <li>Chronic kidney disease (eGFR &lt; 30)</li>
        <li>Current use of blood thinners or anticoagulants that might interfere with NBT</li>
        <li>History of hypersensitivity to soy products</li>
      </ul>
    
      <h4>1.4 Intervention</h4>
      <p>NBT oral dietary supplement: 1 capsule BID (Twice Daily)</p>
    
      <h4>1.5 Outcome Measures</h4>
      <p><strong>Primary Outcome:</strong></p>
      <ul>
        <li>Reduction in arterial plaque assessed by CIMT or CAC score</li>
        <li>CIMT via high-resolution ultrasound</li>
        <li>CAC via CT scan</li>
      </ul>
      <p><strong>Secondary Outcomes:</strong></p>
      <ul>
        <li><strong>Blood Biomarkers:</strong> Fibrinogen, D-dimer, CRP, Lipid profile, PAI-1, tPA</li>
        <li><strong>Blood Pressure:</strong> Systolic and diastolic changes</li>
        <li><strong>Vascular Function:</strong> Flow-mediated dilation (FMD) of brachial artery</li>
      </ul>
    
      <h4>1.6 Study Timeline</h4>
      <ul>
        <li>Screening and Enrollment: 2 weeks</li>
        <li>Treatment Period: 16 weeks</li>
        <li>Study Start Estimate: November 2025</li>
        <li>Recruitment: September - October 2025</li>
        <li>Intervention: November 2025 - February 2026</li>
        <li>Follow-up: March - April 2026</li>
        <li>Post-intervention Assessments: Week 17</li>
        <li>Optional 6-month follow-up for sustained effects</li>
      </ul>
    
      <h4>1.7 Data Collection and Analysis</h4>
      <p><strong>Data Collection:</strong></p>
      <ul>
        <li>Medical history and demographics</li>
        <li>Baseline and post-intervention measurements: arterial plaque, lipid profile, biomarkers, blood pressure, FMD</li>
      </ul>
      <p><strong>Statistical Analysis:</strong></p>
      <ul>
        <li>Primary: Change in CIMT or CAC using paired t-tests or ANCOVA</li>
        <li>Secondary: Correlation with inflammatory and fibrinolytic markers</li>
        <li>Subgroup: Age, sex, and baseline plaque severity</li>
      </ul>
    
      <h4>1.8 Sample Size Calculation</h4>
      <p>Assess whether there is a moderate effect with NBT (e.g., 10-15% reduction in plaque compared to starting point) in the studied population.</p>
    </section>
    
  </section>

  <section id="section2">
    <section id="case-study-2">
      <h2>Asthma Outcome Case Study Outline</h2>
      <p><strong>Evaluating the Effect of a Dietary Supplement containing Nattokinase and soluble Stacked Terpenes (Borneol and Trans Cinnamaldehyde) (NBT) on Arterial Plaque Reduction in Adults with Mild to Moderate Atherosclerosis.</strong></p>
    
      <h3>1. Introduction</h3>
      <h4>1.1 Title</h4>
      <p>Study and evaluation of the effectiveness of NBT supplementation in reducing arterial plaque levels and improving vascular health in adults with mild to moderate atherosclerosis.</p>
    
      <h4>1.2 Study Objectives</h4>
      <p><strong>Primary Objective:</strong> To evaluate the effect of oral NBT supplementation in adults with moderate arterial plaque.</p>
      <p><strong>Secondary Objectives:</strong></p>
      <ul>
        <li>Evaluate quality of life improvements.</li>
        <li>Assess tolerability of NBT supplementation.</li>
      </ul>
    
      <h4>1.3 Study Design</h4>
      <p><strong>Type:</strong> Case study</p>
      <p><strong>Duration:</strong> 16 weeks</p>
      <p><strong>Setting:</strong> Outpatient clinics and research centers</p>
      <p><strong>Participants:</strong></p>
      <ul>
        <li>20 Adults aged 40-75 years</li>
        <li>Diagnosed with mild to moderate atherosclerosis based on medical history and imaging (e.g., carotid ultrasound, CT angiography, or coronary artery calcium score)</li>
        <li>Willing to comply with the study protocol and provide informed consent</li>
        <li>No major cardiovascular events (e.g., myocardial infarction, stroke) in the last 6 months</li>
      </ul>
      <p><strong>Exclusion Criteria:</strong></p>
      <ul>
        <li>Severe cardiovascular disease</li>
        <li>Active bleeding disorders or history of major bleeding</li>
        <li>Pregnancy or breastfeeding</li>
        <li>Chronic kidney disease (eGFR &lt; 30)</li>
        <li>Current use of blood thinners (e.g., warfarin) or other anticoagulants that might interfere with NBT</li>
        <li>History of hypersensitivity to soy products</li>
      </ul>
    
      <h4>1.4 Intervention</h4>
      <p>NBT oral dietary supplement: 1 capsule BID (Twice Daily)</p>
    
      <h4>1.5 Outcome Measures</h4>
      <p><strong>Primary Outcome:</strong></p>
      <ul>
        <li>Reduction in Arterial Plaque as assessed by non-invasive imaging techniques like Carotid Intima-Media Thickness (CIMT) or Coronary Artery Calcium (CAC) Score</li>
        <li>CIMT: measured using high-resolution ultrasound</li>
        <li>CAC: measured using a CT scan to assess calcified plaque</li>
      </ul>
      <p><strong>Secondary Outcomes:</strong></p>
      <ul>
        <li><strong>Blood Biomarkers:</strong> Fibrinogen, D-dimer, CRP, Lipid profile, PAI-1, tPA</li>
        <li><strong>Blood Pressure:</strong> Systolic and diastolic measurements pre- and post-intervention</li>
        <li><strong>Vascular Function:</strong> Flow-mediated dilation (FMD) of the brachial artery</li>
      </ul>
    
      <h4>1.6 Study Timeline</h4>
      <ul>
        <li>Screening and Enrollment: 2 weeks</li>
        <li>Treatment Period: 16 weeks</li>
        <li>Study Start Estimate: November 2025</li>
        <li>Recruitment Period: September - October 2025</li>
        <li>Intervention Period: November 2025 - February 2026</li>
        <li>Follow-up and Analysis: March - April 2026</li>
        <li>Post-intervention Assessments: Week 17</li>
        <li>Optional follow-up at 6 months to assess sustained effects</li>
      </ul>
    
      <h4>1.7 Data Collection and Analysis</h4>
      <p><strong>Data Collection:</strong></p>
      <ul>
        <li>Medical history and demographics at baseline</li>
        <li>Baseline and post-intervention measurements: arterial plaque (CIMT or CAC), lipid profile, biomarkers, blood pressure, FMD</li>
      </ul>
      <p><strong>Statistical Analysis:</strong></p>
      <ul>
        <li>Primary analysis: Change in CIMT or CAC score from baseline to post-treatment (12 weeks) using paired t-tests or ANCOVA adjusted for baseline values</li>
        <li>Secondary analysis: Correlation between plaque reduction and changes in inflammatory/fibrinolytic markers (e.g., fibrinogen, CRP, PAI-1)</li>
        <li>Subgroup analysis: Differences by age, sex, or baseline plaque severity</li>
      </ul>
    
      <h4>1.8 Sample Size Calculation</h4>
      <p>Assess whether there is a moderate effect with NBT (e.g., 10–15% reduction in plaque compared to starting point) in the population studied.</p>
    </section>
    
  </section>

  <section id="section3">
    <section id="case-study-3">
      <h2>Bronchiectasis Outcome Case Study Outline</h2>
      <p><strong>Evaluating the Effect of a Dietary
        Supplement on Pulmonary Function in Children with
        Bronchiectasis</strong></p>
    
      <h3>1. Introduction</h3>
      <h3>1.1 Background Information:</h3>
      <p>Bronchiectasis (BRO) can be a
        genetic or acquired disorder that affects the lungs, pancreas, and
        other organs. Children with BRO often experience chronic
        pulmonary function and respiratory problems.</p>
    
      <h4>1.2 Objective of the Case Study</h4>
      <p>To evaluate the impact of
        Soluble Isolate Extracts of botanical terpenes and oils (BTO) on
        mucus production, respiratory function, and overall response in on
        pulmonary function in 20 children diagnosed with Bronchiectasis
        over a 4-week period.</p>
    
      <h3>2. Study Design</h3>
    
      <h3>2.1 Study Population</h3>
      <ul>
        <li><strong>Sample Size:</strong> 20 children with BRO</li>
        <li><strong>Age Range:</strong> 8–14 years old</li>
        <li><strong>Inclusion Criteria:</strong>
          <ul>
            <li>Diagnosis of BRO from Cystic Fibrosis confirmed by
              genetic testing or sweat chloride test, or Primary Ciliary
              Dyskinesia (PCD)</li>
            <li>Stable clinical condition (no acute exacerbations or
              hospitalizations within the last 30 days).</li>
          </ul>
        </li>
        <li><strong>Exclusion Criteria:</strong>
          <ul>
            <li>Children with severe complications (e.g., liver failure or
              severe gastrointestinal disorders).</li>
            <li>Children with allergies or intolerances to the ingredients
              in the dietary supplement.</li>
          </ul>
        </li>
      </ul>
    
      <h3>2.2 Intervention</h3>
      <h3>Supplementation Protocol:</h3>
      <ul>
        <li><strong>Supplement Type:</strong> Oral dietary supplementation in the form
          of Soluble Isolate Extracts of botanical terpenes and oils
          <strong>(BTO)</strong></li>
        <li><strong>Duration of Treatment::</strong> 4 weeks.</li>
        <li><strong>Administration:</strong> Oral supplementation 2 capsules twice
          daily.</li>
        <li>participants will continue with standard nutritional
management as advised by their healthcare advisor.</li>
      </ul>
    
      <h4>2.3 Outcome Measures</h4>
      <ul>
        <li><strong>Primary Outcome:</strong>
          <ul>
            <li><strong>Pulmonary Function:</strong> Assessed using spirometry to
              measure Forced Expiratory Volume (FEV1) and Forced
              Vital Capacity (FVC).</li>
            <li><strong>Clinical Symptoms:</strong> Frequency and severity of
              respiratory symptoms (cough, wheezing, sputum
              production, etc.) recorded in daily logs.</li>
          </ul>
        </li>
      </ul>
    
      <h3>3. Baseline Data</h3>
      <h3>3.1 Participant Demographics:</h3>
      <ul>
        <li>20 children.</li>
        <li><strong>Age: Range: 8-14 years.</strong></li>
      </ul>
    
      <h3>3.2 Clinical Characteristics</h3>
        <ul>
          <li><strong>Pulmonary Function (FEV1): </strong>Mean of 80% predicted value
            (reflecting mild-to-moderate lung function impairment).</li>
        </ul>

      <h3>4. Nutritional Counseling</h3>
        <ul>
          <li>All participants will continue their regular BRO nutrition treatment.</li>
        </ul>
      <h3>5. Monitoring and Data Collection</h3>
      <h3>Follow-Up Measurements (Daily and weekly):</h3>
        <li><strong>Weight, height, and BMI</strong> will be recorded.</li>
        <li><strong>Spirometry</strong> will be performed every week to measure lung function (FEV1, FVC).</li>
        <li><strong>Clinical Symptom Tracking: </strong>Parents will record daily symptoms in a symptom diary (frequency of coughing, sputum production, and respiratory distress).</li>
      </ul>
    
      <h3>6. Clinical Symptoms / Case Observations:</h3>
      <ul>
        <li>
          <strong>Symptom Frequency: </strong> Evaluate children for reported
          reduction in the frequency of respiratory symptoms -
          coughing and wheezing
        </li>
      </ul>>
    
      <h3>7. Data Collection Timeline</h3>
      <ol>
        <li><strong>Pre-treatment (Week 0):</strong> Baseline measurements (FEV1,
          mucus production, asthma control, quality of life).</li>
        <li><strong>Mid-treatment (Week 2):</strong> Follow-up assessment for
          preliminary changes.</li>
        <li><strong>Post-treatment (Week 4):</strong> Final measurements and data
          collection.</li>
        <li><strong>Follow-up (Optional):</strong> A follow-up period (e.g., 1-month
          post-treatment) to assess any lasting effects.</li>
      </ol>
    
      <h3>Considerations</h3>
      <ul>
        <li><strong>Informed Consent:</strong> Written informed consent will be obtained
          from all participants before enrollment.</li>
        <li><strong>Data Privacy:</strong> All participant data will be kept confidential, and
          results will be reported in aggregate form to ensure participant
          privacy.</li>
      </ul>
    
      <h3>Timeline</h3>
      <ul>
        <li><strong>Screening and Enrollment:</strong> 2 weeks</li>
        <li><strong>Treatment Period:</strong> 4 weeks</li>
        <li><strong>Study Start Estimate:</strong> November 2025.</li>
        <li><strong>Recruitment Period:</strong> September–October 2025.</li>
        <li><strong>Intervention Period:</strong> November 2025 – January 2026.</li>
        <li><strong>Follow-up and Analysis:</strong> February 2026</li>
      </ul>
    
      <h3>10. Conclusion</h3>
      <p>This study will assess the effect of soluble, botanical terpenes and
        oils <strong>(BTO)</strong> on mucus production, respiratory function, and overall
        response in children with Bronchiectasis.</p>
    </section>
    
  </section>

  <section id="section4">
    <section id="crohns-study">

      <h2>Crohn's Outcome Case Study Outline</h2>
    <p><strong>Evaluating the Effect of Butyrate Supplementation on Symptoms of Crohn’s Disease</strong></p>
      <h3>1. Title</h3>
      <p>Study and Evaluation of Micro Dose, soluble, sustained release,
        Butyrate Supplementation to Observe Clinical Outcomes in adults
        with Crohn's Disease</p>
    
      <h3>2. Study Objectives</h3>
      <ul>
        <li><strong>Primary Objective:</strong> To evaluate the effect of micro dose oral butyrate
          supplementation in adults with moderate Crohn's disease over 4
          weeks.</li>
        <li><strong>Secondary Objectives:</strong>
          <ul>
            <li>Evaluate quality of life improvements.</li>
            <li>Assess tolerability of butyrate supplementation.</li>
          </ul>
        </li>
      </ul>
    
      <h3>3. Study Design</h3>
      <ul>
        <li><strong>Type:</strong> Case study.</li>
        <li><strong>Duration:</strong> 4 weeks.</li>
        <li><strong>Setting:</strong> Outpatient clinics and research centers.</li>
        <li><strong>Participants:</strong> 20 adults aged 18-65 years with a confirmed diagnosis of moderate Crohn's disease (based on the Crohn's Disease Activity Index, CDAI 150–450).</li>
      </ul>
    
      <h3>4. Inclusion Criteria</h3>
      <ul>
        <li>Age 18–65 years.</li>
        <li>Diagnosis of moderate Crohn&#39;s disease with disease activity score
          (CDAI) of 150-450.</li>
        <li>Signed informed consent.</li>
      </ul>
    
      <h3>5. Exclusion Criteria</h3>
      <ul>
        <li>Severe Crohn's disease (CDAI &gt;450) or active complications (e.g., fistulas, strictures).</li>
        <li>Recent use of biologic therapies or systemic corticosteroids within 4 weeks.</li>
        <li>History of significant gastrointestinal surgery (except appendectomy).</li>
        <li>Pregnancy, breastfeeding, or plans to become pregnant during the study.</li>
        <li>Known allergies to butyrate or components of the supplement.</li>
      </ul>
    
      <h3>6. Intervention</h3>
      <h3>Butyrate Supplementation Protocol:</h3>
      <ul>
        <li><strong>Supplement Type:</strong> Oral micro dose, soluble, individual molecule butyrate supplementation, in sustained release capsules.</li>
        <li><strong>Exclusion of less effective forms of butyrate:</strong> Sodium or Calcium butyrate or butyrate tributyrin (triglyceride form)</li>
        <li><strong>Duration of Treatment:</strong> 4 weeks.</li>
        <li><strong>Administration:</strong> Oral supplementation 5 capsules twice daily.</li>
      </ul>
      
    
      <h3>7. Outcome Measures</h3>
      
        <p>Primary Outcome:</p>
        <ul>
          <li>Disease Activity: Evaluate any change in Crohn's Disease Activity Index (CDAI) from baseline to 4 weeks.</li>
        </ul>
        <h3>Secondary Outcomes:</h3>
          <ul>
            <li><strong>Quality of Life:</strong> Measured using the Inflammatory Bowel Disease Questionnaire (IBDQ) to assess changes in physical, social, and emotional well-being.</li>
          </ul>
    
      <h3>8. Considerations</h3>
      <ul>
        <li><strong>Informed Consent:</strong> Written informed consent will be obtained from all participants before enrollment.</li>
        <li><strong>Data Privacy:</strong> All participant data will be kept confidential, and results will be reported in aggregate form to ensure participant privacy.</li>
      </ul>
    
      <h3>9. Timeline</h3>
      <ul>
        <li><strong>Screening and Enrollment:</strong> 2 weeks</li>
        <li><strong>Treatment Period:</strong> 4 weeks</li>
        <li><strong>Study Start Estimate:</strong> November 2025</li>
        <li><strong>Recruitment Period:</strong> September – October 2025</li>
        <li><strong>Intervention Period:</strong> November 2025 - January 2026.</li>
        <li><strong>Follow-up and Analysis:</strong> February 2026.</li>
      <h3>10. Conclusion</h3>
      <p>This study will assess the effect of soluble, micro dose butyrate
        supplementation in evaluating symptoms of Crohn's disease, focusing on
        disease activity, inflammation, quality of life, and gut microbiota changes. If
        
        proven effective, butyrate could offer a natural, adjunctive means to support
        Crohn's disease adults, with minimal side effects.</p>
    
    
    
  </section>
  </section>
  <section id="section5">
    <section id="case-study-5">
      <h2>Cystic Fibrosis Outcome Case Study Outline</h2>
      <p><strong>Evaluating the Effect of a Dietary Supplement on Pulmonary Function in Children with Cystic Fibrosis</strong></p>
    
      <h3>1. Introduction</h3>
      <h3><strong>1.1 Background Information:</strong></h3><p>Cystic Fibrosis (CF) is a genetic disorder that affects the lungs, pancreas, and other organs. Children with CF often experience chronic pulmonary function and respiratory problems.</p>
      <h3><strong>1.2 Objective:</strong></h3><p>To evaluate the impact of Soluble Isolate Extracts of botanical terpenes and oils <strong>(BTO)</strong> on pulmonary function in 20 children diagnosed with Cystic Fibrosis over a 4-week period.</p>
      </ul>
    
      <h3>2. Study Design</h3>
      <h3>2.1. Study Population:</h3>
      <ul>
        <li><strong>Sample Size:</strong> 20 children with CF</li>
        <li><strong>Age Range:</strong> 8–14 years</li>
        <li><strong>Inclusion Criteria:</strong>
          <ul>
            <li>Diagnosis of Cystic Fibrosis confirmed by genetic testing or sweat chloride test.</li>
            <li>Stable clinical condition (no acute exacerbations or hospitalizations within the last 30 days).</li>
          </ul>
        </li>
        <li><strong>Exclusion Criteria:</strong>
          <ul>
            <li>Children with severe CF-related complications (e.g., liver failure or severe gastrointestinal disorders).</li>
            <li>Children with allergies or intolerances to the ingredients in the dietary supplement.</li>
          </ul>
        </li>
      </ul>
    
      <h3>2.2. Intervention:</h3>
      <h3>Supplementation Protocol:</h3>
      <ul>
        <li><strong>Supplement Type:</strong> Oral dietary supplementation in the form of Soluble Isolate Extracts of botanical terpenes and oils <strong>(BTO)</strong></li>
        <li><strong>Duration of Treatment:</strong> 4 weeks.</li>
        <li><strong>Administration:</strong> Oral supplementation 2 capsules twice daily.</li>
        <li>participants will continue with standard nutritional management as advised by their healthcare advisor.</li>
      </ul>
    
      <h3>2.3. Outcome Measures:</h3>
      <ul>
        <li><strong>Primary Outcome:</strong>
          <ul>
            <li><strong>Pulmonary Function:</strong> Assessed using spirometry to measure Forced Expiratory Volume (FEV1) and Forced Vital Capacity (FVC).</li>
            <li><strong>Clinical Symptoms:</strong> Frequency and severity of respiratory symptoms (cough, wheezing, sputum production, etc.) recorded in daily logs.</li>
          </ul>
        </li>
      </ul>
    
      <h3>3. Baseline Data</h3>
      <h3>3.1. Participant Demographics:</h3>
      <ul>
        <li>20 children.</li>
        <li><strong>Age:</strong> Range: 8-14 years.</li>
      </ul>
      <h3>3.2. Clinical Characteristics:</h3>
      <ul>
        <li><strong>Pulmonary Function (FEV1):</strong> Mean of 80% predicted value (reflecting mild-to-moderate lung function impairment).</li>
      </ul>
    
      <h3>4. Nutritional Counseling</h3>
      <ul>
        <li>All participants will continue their regular CF nutrition treatment.</li>
      </ul>
    
      <h3>5. Monitoring and Data Collection</h3>
      <p><strong>Follow-Up Measurements (Daily and weekly):</strong></p>
      <ul>
        <li><strong>Weight, height, and BMI</strong> will be recorded.</li>
        <li><strong>Spirometry</strong>  will be performed every week to measure lung function (FEV1, FVC).</li>
        <li><strong>Clinical Symptom Tracking:</strong> Parents will record daily symptoms in a symptom diary (frequency of coughing, sputum production, and respiratory distress).</li>
      </ul>
    
      <h3>6. Clinical Symptoms</h3>
      <ul>
        <li><strong>Symptom Frequency: </strong>Evaluate children for reported reduction in the frequency of respiratory symptoms - coughing and wheezing</li>
      </ul>>
    
      <h3>7. Data Collection Timeline</h3>
      <ol>
        <li><strong>Pre-treatment (Week 0): </strong> Baseline measurements (FEV1, mucus production, asthma control, quality of life).</li>
        <li><strong>Mid-treatment (Week 2):</strong> Follow-up assessment for preliminary changes.</li>
        <li><strong>Post-treatment (Week 4):</strong> Final measurements and data collection.</li>
        <li><strong>Follow-up (Optional):</strong> A follow-up period (e.g., 1-month post-treatment) to assess any lasting effects.</li>
      </ol>
    
      <h3>Considerations</h3>
      <ul>
        <li><strong>Informed Consent:</strong> Written informed consent will be obtained from all participants before enrollment.</li>
        <li><strong>Data Privacy:</strong> All participant data will be kept confidential, and results will be reported in aggregate form to ensure participant privacy.</li>
      </ul>
    
      <h3>Timeline</h3>
      <ul>
        <li><strong>Screening and Enrollment:</strong> 2 weeks</li>
        <li><strong>Treatment Period:</strong> 4 weeks</li>
        <li><strong>Study Start estimate:</strong> November 2025.</li>
        <li><strong>Recruitment Period:</strong> September -October 2025.</li>
        <li><strong>Intervention Period:</strong> November 2025 - January 2026.</li>
        <li><strong>Follow-up and Analysis:</strong> February 2026.</li>
      </ul>
    
      <h3>10. Conclusion</h3>
      <p>This study will assess the effect of soluble, botanical terpenes and
        oils <strong>(BTO)</strong>> on mucus production, respiratory function, and overall
        response in children with Cystic Fibrosis.</p>
    </section>
    
  </section>
  <section id="section6">
    <section id="case-study-6">
      <h2>Parkinson's Outcome Case Study Outline</h2>
      <p><strong>Evaluating the Effect of Micro Dose, Soluble Butyrate and Soluble Glutathione Supplementation on Parkinson’s Disease and Parkinsonism.</strong></p>
    
      <h3>1. Introduction</h3>
      <h3>Title</h3>
      <p>Study and Evaluation of Micro Dose, Soluble, Sustained Release Butyrate and Glutathione (SB-SG) Supplementation to Observe Clinical Outcomes in Adults with Parkinson’s Disease</p>
    
      <h3>2. Study Objectives</h3>
      <ul>
        <li><strong>Primary Objective:</strong> To evaluate the effect of (SB-SG) in adults with Parkinson’s Disease and Parkinsonism over 4 weeks.</li>
        <li><strong>Secondary Objectives:</strong>
          <ul>
            <li>Evaluate quality of life improvements.</li>
            <li>Assess tolerability of both supplements.</li>
          </ul>
        </li>
      </ul>
    
      <h3>3. Study Design</h3>
      <ul>
        <li><strong>Type:</strong> Case study.</li>
        <li><strong>Duration:</strong> 4 weeks.</li>
        <li><strong>Setting:</strong> Outpatient clinics and research centers.</li>
        <li><strong>Participants:</strong> 20 adults with a confirmed diagnosis Parkinson’s.</li>
        <li><strong>Subject Criteria.</strong> Subjects shall be elderly and initially present with mild to moderate Parkinson’s Disease or Parkinsonism.</li>
        <li><strong>Protocols. The protocols for screening, testing, and reporting of (SB-SG) shall be:</strong>
          <ul>
            <li>Clinically screening potential test candidates for Brady Kinesis, Cog-Wheeling, Pill-Rolling, Masked Facies, Festinating Gait, and Retro-pulsion (the “Parkinson’s Clinical Screening”</li>
          </ul>
        </li>
      </ul>
      <h3>Intervention</h3>
      <h3>4. Supplementation Protocol</h3>
      <ul>
        <li><strong>Supplement Type:</strong> Oral dose <strong>(SB-SG)</strong></li>
        <li><strong>Exclusion of less effective forms of butyrate:</strong> Sodium or Calcium butyrate or butyrate tributyrin (triglyceride form)</li>
        <li><strong>Duration of Treatment:</strong> 4 weeks.</li>
      </ul>
      <h3>Administration:</h3>
      <ul>
        <li><strong>Butyrate: 5 caps BID (twice daily) for 1 week, then 3 caps BID. If any regression, return to original dose. Glutathione: 3 caps BID for 1 week, then 2 caps BID. If any regression, return to original dose.</strong></li>
        <li><strong>Ensure that subjects do not consume alcohol or acetaminophen during Testing Period.</strong></li>
      </ul>
      
    
      <h3>5. Diet Protocol</h3>
      <ul>
        <li><strong>Eliminate all intake of calcium propionate and propionic acid in any form (i.e., preserved breads and chips, etc.).</strong></li>
        <li><strong>Eliminate most dietary soluble fiber for 3 weeks. </strong></li>
        <li><strong>Ensure consumption of insoluble fiber for 3 weeks.</strong></li>
        <li>Daily diet logged by subject during case study.</li>
        <li>Day 30 Endpoint, complete Parkinson’s Clinical Screening and Parkinson’s Questionnaire.</li>
      </ul>
    
      <h3>6. Considerations</h3>
      <ul>
        <li><strong>Informed Consent:</strong> Written informed consent will be obtained from all participants before enrollment.</li>
        <li><strong>Data Privacy:</strong> All participant data will be kept confidential, and results will be reported in aggregate form to ensure participant privacy.</li>
      </ul>
    
      <h3>7. Timeline</h3>
      <ul>
        <li><strong>Screening and Enrollment:</strong> 2 weeks</li>
        <li><strong>Treatment Period:</strong> 4 weeks</li>
        <li><strong>Study Start estimate:</strong> November 2025.</li>
        <li><strong>Recruitment Period:</strong> September -October 2025.</li>
        <li><strong>Intervention Period:</strong> November 2025 - January 2026.</li>
        <li><strong>Follow-up and Analysis:</strong> February 2026.</li>
      </ul>
    </section>
    
  </section>


  <section id="section7">
    <section id="case-study-7">
      <h2>Ulcerative Colitis Outcome Case Study Outline</h2>
      <p><strong>Evaluating the Effect of Butyrate Supplementation on Symptoms of Ulcerative Colitis (UC)</strong></p>
    
      <h3>1. Introduction</h3>
      <h3>1. Title</h3>
      <p>Study and Evaluation of Micro Dose, soluble, sustained release, Butyrate Supplementation to Observe Clinical Outcomes in adults with Ulcerative Colitis Disease</p>
    
      <h3>2. Study Objectives</h3>
      <ul>
        <li><strong>Primary Objective:</strong> To evaluate the effect of micro dose oral butyrate supplementation in adults with moderate Ulcerative Colitis disease over 4 weeks.</li>
        <li><strong>Secondary Objectives:</strong>
          <ul>
            <li>Evaluate quality of life improvements.</li>
            <li>Assess tolerability of butyrate supplementation.</li>
          </ul>
        </li>
      </ul>
    
      <h3>3. Study Design</h3>
      <ul>
        <li><strong>Type:</strong> Case study.</li>
        <li><strong>Duration:</strong> 4 weeks</li>
        <li><strong>Setting:</strong> Outpatient clinics and research centers</li>
        <li><strong>Participants:</strong> 20 adults aged 18-65 years with a confirmed diagnosis of moderate Ulcerative Colitis disease (based on Inflammatory Markers (C-Reactive protein, CRP): Elevated.</li>
      </ul>
    
      <h3>4. Inclusion Criteria</h3>
      <ul>
        <li>Age 18-65 years.</li>
        <li>Diagnosis of moderate Ulcerative Colitis disease with <strong>Disease Activity Index (DAI):</strong> 14 (on a scale from 0 to 20, where higher numbers indicate more severe symptoms)</li>
        <li><strong>Inflammatory Markers (C-reactive protein, CRP):</strong> Elevated (10 mg/L; normal &lt;3 mg/L) </li>
        <li><strong>Stool Frequency:</strong> 3-7 episodes per day</li>
        <li><strong>Quality of Life (QoL):</strong> Reported as “moderately impaired” based on the IBDQ (Inflammatory Bowel Disease Questionnaire) score.</li>
        <li>Signed informed consent.</li>
      </ul>
    
      <h3>5. Intervention</h3>
      <h4>5.1. Butyrate Supplementation Protocol:</h4>
      <ul>
        <li>Supplement Type: Oral micro dose, soluble, individual molecule butyrate supplementation, in sustained release capsules.</li>
        <li>Exclusion of less effective forms of butyrate: Sodium or Calcium butyrate or butyrate tributyrin (triglyceride form)</li>
        <li>Duration of Treatment: 4 weeks.</li>
        <li>Administration: Oral supplementation 5 capsules twice daily.</li>
      </ul>
      
    
      <h4>5.2. Exclusion Criteria</h4>
      <ul>
        <li>Severe Ulcerative Colitis diagnosis or active complications (e.g., fistulas, strictures).</li>
        <li>Recent use of biologic therapies or systemic corticosteroids within 4 weeks.</li>
        <li>History of significant gastrointestinal surgery (except appendectomy).</li>
        <li>Pregnancy, breastfeeding, or plans to become pregnant during the study.</li>
        <li>Known allergies to butyrate or components of the supplement.</li>
      </ul>
      
    
      <h3>6. Intervention</h3>
      <ul>
        <li>Investigation Group: Oral micro dose soluble, individual molecule butyrate supplementation, in sustained release capsules.</li>
      </ul>
      
    
      <h3>7. Outcome Measures</h3>

      <h4>7.1. Primary Outcome:</h4>
      <ul>
        <li><strong>Symptom Reduction:</strong> Measured using the Disease Activity Index (DAI), specifically focusing on improvements in stool frequency, abdominal pain, and presence of blood in stools.</li>
      </ul>
      
      <h4>7.2. Secondary Outcomes:</h4>
      <ul>
        <li><strong>Inflammatory Markers:</strong> CRP levels and fecal calprotectin (a marker of intestinal inflammation).</li>
        <li><strong>Quality of Life (QoL):</strong> Assessed before and after supplementation using the IBDQ.</li>
        <li><strong>Self-Reported Symptoms:</strong> Frequency and severity of diarrhea, bloating, and abdominal discomfort.</li>
      </ul>
      
    
      <h3>8. Considerations</h3>
      <ul>
        <li><strong>Informed Consent:</strong> Written informed consent will be obtained from all participants before enrollment.</li>
        <li><strong>Data Privacy:</strong> All participant data will be kept confidential, and results will be reported in aggregate form to ensure participant privacy.</li>
      </ul>
      
      <h3>9. Timeline</h3>
      <ul>
        <li><strong>Screening and Enrollment:</strong> 2 weeks</li>
        <li><strong>Treatment Period:</strong> 4 weeks</li>
        <li><strong>Study Start estimate:</strong> November 2025.</li>
        <li><strong>Recruitment Period:</strong> September -October 2025.</li>
        <li><strong>Intervention Period:</strong> November 2025 - January 2026.</li>
        <li><strong>Follow-up and Analysis:</strong> February 2026.</li>
      </ul>
      
      <h3>10. Conclusion</h3>
      <p>
        This study will assess the effect of soluble, micro dose butyrate supplementation in evaluating symptoms of Ulcerative Colitis disease, focusing on disease activity, inflammation, quality of life, and gut microbiota changes. If proven effective, butyrate could offer a natural, adjunctive means to support Ulcerative Colitis disease adults, with minimal side effects.
      </p>
      
 </section>
    
  </section>
  <!-- <section id="section8">
    <h2>Section 4: Billing and Payments</h2>
    <p>Answers to common billing questions and how to manage your account.</p>
  </section>
  <section id="section9">
    <h2>Section 4: Billing and Payments</h2>
    <p>Answers to common billing questions and how to manage your account.</p>
  </section> -->

</body>
</html>

